Blog

The latest thoughts from Medicines Law & Policy partners.

wine glass half full

Transfer of technology and know-how for the production of pandemic-related health products in the...

A version of this brief was published on 13 June '25 by the Graduate Institute as part of their 'Governing Pandemic Snapshot' series: https://www.governingpandemics.org/gp-snapshot During...

Wrapping up 2019 – Noteworthy Medicines Law and Policy Events

2019 had its share of noteworthy medicines law and policy events. It was also a year that saw eye-popping new levels of pharmaceutical pricing....

Vaccine knowledge needs to be a global public good: Remarks to the World Trade...

Ellen ‘t Hoen, Medicines Law & Policy, at the World Trade Organization-World Health Organization High-Level Dialogue on Expanding COVID-19 Vaccine Manufacturing to Promote Equitable...

Cystic Fibrosis Medicines Wars in Europe

Monday 4 February, the UK parliament will debate the issuing of a compulsory licence by the government, called ‘Crown use’, for the cystic fibrosis...

The world needs a signal that multilateralism works: ML&P opening statement to the INB13,...

Thank you for the opportunity to make a brief statement. The negotiations for the Pandemic Agreement enter the final phase. We hope and wish for...

Wrapping up 2024: Noteworthy events in medicines law and policy around the globe

Welcome to Medicines Law & Policy’s  end of the year blog, our highly biased annual overview of memorable medicines law and policy events. January At the...

Cancer Drug Pricing on the World Health Organization’s Executive Board Agenda

On Thursday 24 January, the World Health Organization’s 144th Executive Board meeting will kick off in Geneva. One of the agenda items is access...

The European Commission’s proposal on a new EU-wide compulsory licensing regime

Guest author Olga Gurgula is a Senior Lecturer in Intellectual Property Law at Brunel Law School, Brunel University London A recent international health emergency, the...

The European Commission’s compulsory licensing proposals are sensible but do not go far enough

An earlier version of this comment was published in Barron's on 21 July 2023. A Spanish translation of it is also available from El...

Thanks to the European Commission, Biogen can extend Tecfidera monopoly for at least two...

According to an investigation by Follow the Money, a Dutch investigative journalism outlet, the European Commission restored the market exclusivity of Tecfidera, a multiple...